Headache Treatment Options

References

1. 1.↵
   1. Rasmussen BK,
   2. Jensen R,
   3. Schroll M,
   4. et al

   . Epidemiology of headache in a general population—a prevalence study. J Clinical Epidemiology 1991;44:1147–57.

   OpenUrl
2. 2.↵
   National Ambulatory Medical Care survey at the CDC. Available at: https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2019-namcs-web-tables-508.pdf. Accessed May 18, 2023.
3. 3.↵
   1. Robbins MS

   . Diagnosis and management of headache: a review. JAMA 2021;325:1874–85.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Viera AJ,
   2. Antono B

   . Acute headache in adults: a diagnostic approach. Am Fam Physician 2022;106:260–8.

   OpenUrlPubMed
5. 5.↵
   1. Chowdhury D

   . Tension type headache. Ann Indian Acad Neurol 2012;15:S83–S88.

   OpenUrlPubMed
6. 6.↵
   1. Schindler EA,
   2. Burish MJ

   . Recent advances in the diagnosis and management of cluster headache. BMJ 2022;376:e059577.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Weaver-Agostoni J

   . Cluster headache. Am Fam Physician 2013;88:122–8.

   OpenUrlPubMed
8. 8.↵
   1. Mayans L,
   2. Walling A

   . Acute migraine headache: treatment strategies. Am Fam Physician 2018;97:243–51.

   OpenUrlPubMed
9. 9.↵
   1. Kristoffersen ES,
   2. Lundqvist C

   . Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87–99.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Arnold M

    . Headache Classification Committee of the International Headache Society (IHS): the international classification of headache disorders. Cephalalgia 2018;38:1–211.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Lipton RB

    . Risk factors for and management of medication-overuse headache. Continuum: Lifelong Learning in Neurology 2015;21:1118–31.

    OpenUrlPubMed
12. 12.↵
    1. Ahdoot E,
    2. Cohen F

    . Unraveling the MSG-headache controversy: an updated literature review. Current Pain and Headache Reports 2023;1–6.
13. 13.↵
    1. Pistoia F,
    2. Salfi F,
    3. Saporito G,
    4. et al

    . Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities. J Headache Pain 2022;23:110–9.

    OpenUrlPubMed
14. 14.↵
    1. Nicholson RA,
    2. Houle TT,
    3. Rhudy JL,
    4. et al

    . Psychological risk factors in headache: CME. Headache 2007;47:413–26.

    OpenUrlPubMedWeb of Science
15. 15.↵
    1. Seng EK,
    2. Buse DC,
    3. Klepper JE,
    4. et al

    . Psychological factors associated with chronic migraine and severe migraine‐related disability: an observational study in a tertiary headache center. Headache 2017;57:593–604.

    OpenUrlPubMed
16. 16.↵
    1. Vuralli D,
    2. Ayata C,
    3. Bolay H

    . Cognitive dysfunction and migraine. J Headache Pain 2018;19:1–14.

    OpenUrlPubMed
17. 17.↵
    1. Urits I,
    2. Patel M,
    3. Putz ME,
    4. et al

    . Acupuncture and its role in the treatment of migraine headaches. Neurol Ther 2020;9:375–94.

    OpenUrlPubMed
18. 18.↵
    1. Coeytaux RR,
    2. Befus D

    . Role of acupuncture in the treatment or prevention of migraine, tension‐type headache, or chronic headache disorders. Headache 2016;56:1238–40.

    OpenUrlPubMed
19. 19.↵
    1. Smith MS,
    2. Olivas J,
    3. Smith K

    . Manipulative therapies: what works. Am Fam Physician 2019;99:248–52.

    OpenUrlPubMed
20. 20.↵
    1. Lee E,
    2. Moloney S,
    3. Talsma J,
    4. et al

    . Osteopathic manipulative treatment considerations in tension-type headache. J Osteopathic Medicine 2019;119:e40–e41.

    OpenUrl
21. 21.↵
    1. Alexander J

    . Resolution of new daily persistent headache after osteopathic manipulative treatment. J Osteopathic Medicine 2016;116:182–5.

    OpenUrl
22. 22.↵
    1. Penzien DB,
    2. Irby MB,
    3. Smitherman TA,
    4. et al

    . Well-established and empirically supported behavioral treatments for migraine. Curr Pain Headache Rep 2015;19.
23. 23.↵
    1. Singer AB,
    2. Buse DC,
    3. Seng EK

    . Behavioral treatments for migraine management: useful at each step of migraine care. Curr Neurol Neurosci Rep 2015;15:1–8.

    OpenUrlCrossRef
24. 24.↵
    1. Linde K,
    2. Allais G,
    3. Brinkhaus B,
    4. et al

    . Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016;6.
25. 25.↵
    1. Chen Y-Y,
    2. Li J,
    3. Chen M,
    4. et al

    . Acupuncture versus propranolol in migraine prophylaxis: an indirect treatment comparison meta-analysis. J Neurol 2020;267:14–25.

    OpenUrlPubMed
26. 26.↵
    1. Patel PS,
    2. Minen MT

    . Complementary and integrative health treatments for migraine. J Neuro-Ophthalmology 2019;39:360–9.

    OpenUrlPubMed
27. 27.↵
    1. Gerwig M,
    2. Niehaus L,
    3. Stude P,
    4. et al

    . Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation. J Headache Pain 2012;13:83–9.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Schrader H,
    2. Stovner LJ,
    3. Helde G,
    4. et al

    . Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. Bmj 2001;322:19–22.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Banzi R,
    2. Cusi C,
    3. Randazzo C,
    4. et al

    . Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev 2015;4.
30. 30.↵
    1. Ailani J,
    2. Burch RC,
    3. Robbins MS

    , the Board of Directors of the American Headache Societyet al. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021;61:1021–39.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. O’Connell S,
    2. Dale M,
    3. Morgan H,
    4. et al

    . gammaCore for cluster headaches: a NICE medical technologies guidance. PharmacoEconomics-Open (2021):1–10.
32. 32.↵
    1. Moisset X,
    2. Pereira B,
    3. Ciampi de Andrade D,
    4. et al

    . Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 2020;21:142–14.

    OpenUrlPubMed
33. 33.↵
    1. Starling AJ,
    2. Tepper SJ,
    3. Marmura MJ,
    4. et al

    . A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018;38:1038–48.

    OpenUrlCrossRefPubMed
34. 34.
    1. Tepper SJ,
    2. Lin T,
    3. Montal T,
    4. et al

    . Real-world experience with remote electrical neuromodulation in the acute treatment of migraine. Pain Med 2020;21:3522–9.

    OpenUrlPubMed
35. 35.↵
    1. Rist PM,
    2. Hernandez A,
    3. Bernstein C,
    4. et al

    . The impact of spinal manipulation on migraine pain and disability: a systematic review and meta‐analysis. Headache 2019;59:532–42.

    OpenUrlPubMed
36. 36.↵
    1. Stanak M,
    2. Wolf S,
    3. Jagoš H,
    4. et al

    . The impact of external trigeminal nerve stimulator (e-TNS) on prevention and acute treatment of episodic and chronic migraine: a systematic review. J Neurological Sciences 2020;412:116725.

    OpenUrl
37. 37.↵
    1. Adragna V,
    2. Bertino AS,
    3. Carano M,
    4. et al

    . Migraine without aura and osteopathic medicine, a non-pharmacological approach to pain and quality of life: open pilot study. J Headache Pain 2015;16:A180.

    OpenUrlPubMed
38. 38.↵
    1. Cerritelli F,
    2. Lacorte E,
    3. Ruffini N,
    4. et al

    . Osteopathy for primary headache patients: a systematic review. J Pain Res 2017;10:601–11.

    OpenUrlPubMed
39. 39.↵
    1. Slattengren AH,
    2. et al

    . Best uses of osteopathic manipulation. J Family Practice 2017;66:743–8.

    OpenUrl
40. 40.↵
    1. Gelfand AA,
    2. Goadsby PJ

    . A neurologist’s guide to acute migraine therapy in the emergency room. Neurohospitalist 2012;2:51–9.

    OpenUrlCrossRefPubMed
41. 41.
    1. Huang T,
    2. Xu Y,
    3. Chen Y,
    4. et al

    . Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: a meta‐analysis. Brain Behav 2022;12:e2542.

    OpenUrlPubMed
42. 42.↵
    1. Lipton RB,
    2. Croop R,
    3. Stock DA,
    4. et al

    . Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. The Lancet Neurology 2023;22:209–17.

    OpenUrlPubMed